LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that it has launched Ondansetron Injection, USP, the generic equivalent of GlaxoSmithKline’s Zofran® Injection. According to IMS, sales in 2005 of ondansetron in the United States exceeded $587 million. The company markets ondansetron in AP-rated single-dose and multiple-dose bar coded, latex-free vials.
